The Endocyte, Inc. (NASDAQ:ECYT) on Mar. 27 announced the pricing of an underwritten public offering of 4,500,000 shares of its common stock at a price to the public of $21.00 per share. The gross proceeds to Endocyte from this offering, before deducting underwriting discounts and commissions and other offering expenses payable by Endocyte, will be approximately $94.5 million. Endocyte has also granted the underwriters a 30-day option to purchase up to an additional 675,000 shares of common stock. The offering is expected to close on or about April 2, 2014, subject to customary closing conditions. Endocyte, Inc. (NASDAQ:ECYT) shares after opening at $22.10 moved to $21.96 on last trade day and at the end of the day closed at $21.96. Company price to sales ratio in past twelve months was calculated as 12.27 and price to cash ratio as 5.35. Endocyte, Inc. (NASDAQ:ECYT) showed a negative weekly performance of -22.04%.
Orthofix International NV (NASDAQ:OFIX) Chief executive officer could not fail to point out that2013 was a transitional and challenging year for the company as it grappled with several headwinds behind the scene,while presenting fourth quarter and full year result for the period ending December 31, 2013. The year saw the diversified medical device company implement a number of changes in its various business divisions, aimed at reviving the company’s growth metrics.Orthofix International NV (NASDAQ:OFIX) shares fell -0.30% in last trading session and ended the day on $30.29. OFIX return on equity ratio is recorded as 10.80% and its return on assets is 7.80%. Orthofix International NV (NASDAQ:OFIX) yearly performance is -15.56%.
Keryx Biopharmaceuticals (NASDAQ:KERX) could get an unexpected boost from a bill introduced by House Republicans this week. Keryx produces an oral medication called Zerenex that is used in the treatment of end stage renal disease (ESRD) and which is currently going to be included in the ESRD bundled payment system starting 2016, putting pressure on its price. Keryx Biopharmaceuticals (NASDAQ:KERX) shares moved down -1.60% in last trading session and was closed at $16.61, while trading in range of $16.41-$17.14. Keryx Biopharmaceuticals (NASDAQ:KERX) year to date performance is 28.26%.
Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA), in whose stock analysts at TheStreet remain bearish with a sell recommendation, could get away with an opportunity to develop a generic version of Copaxone if the U.S. top court doesn’t grant the wishes of Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA). In July 2013, a court ruling favored the position of MNTA and other cheap generic drug manufacturers seeking to bring to the market a generic version of Copaxone. But TEVA is firmly against such moves as they will effectively erode its drug patent protection and expose it to intense market competition. A decision as to whether the top court will review the earlier ruling is expected earliest on March 31. Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) is still soaked in losses. The company reported loss of 59 cents against 45 cents loss which Wall Street expected in its most recent quarter. Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) weekly performance is 0.08%. On last trading day company shares ended up $49.45. Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) distance from 50-day simple moving average is 5.79%. Analysts mean target price for the company is $50.60.